Teva Pharmaceuticals Recalls Prazosin Hydrochloride Nationwide Over Carcinogenic Nitrosamine Impurity
Teva Pharmaceuticals USA, Inc. has initiated a U.S. nationwide Class II recall for 291,512 bottles of Prazosin Hydrochloride Capsules. The action stems from Current Good Manufacturing Practices (CGMP) deviations, specifically N-nitroso Prazosin impurity C exceeding acceptable carcinogenic intake limits. This event underscores critical supply chain vulnerabilities and heightened regulatory scrutiny on nitrosamine contamination in generic pharmaceuticals.
FDA Initiates Class II Recall for Teva's Prazosin Hydrochloride Due to Nitrosamine Impurity
Teva Pharmaceuticals USA, Inc. has initiated a voluntary, firm-initiated Class II recall, designated D-0105-2026, impacting its Prazosin Hydrochloride Capsules, USP, 2 mg. This significant regulatory action, initiated on October 7, 2025, and reported to the FDA on November 5, 2025, affects 291,512 bottles distributed across the U.S. nationwide. The core issue identified is a deviation from Current Good Manufacturing Practices (CGMP), specifically concerning test results for N-nitroso Prazosin impurity C. These impurity levels were found to be above the acceptable intake limit as defined by the Carcinogenic Potency Categorization Approach (CPCA). For procurement directors and supply chain VPs, this recall necessitates an immediate assessment of existing Prazosin Hydrochloride inventory and potential supply disruptions. The presence of a nitrosamine impurity, N-nitroso Prazosin impurity C, exceeding CPCA limits, signals a critical quality control failure. This directly impacts patient safety and market availability for a widely prescribed alpha-1 adrenergic blocker used in hypertension management. Companies relying on Teva for this molecule must swiftly identify affected lots, which include various expiration dates ranging from December 2025 to February 2028, under NDCs 0093-4068-01 (100 Capsules) and 0093-4068-10 (1000 Capsules).
Market Impact and Supply Chain Vulnerabilities for Prazosin Hydrochloride
The recall of 291,512 bottles of Prazosin Hydrochloride Capsules, USP, 2 mg, distributed U.S. nationwide, represents a substantial volume within the American pharmaceutical market for this specific molecule. Prazosin Hydrochloride, approved under ANDA071745, is a crucial generic medication for managing hypertension and benign prostatic hyperplasia. Teva Pharmaceuticals USA, Inc., based in Parsippany, NJ, is a significant player in the generic drug landscape. The broad distribution pattern means that pharmacies, hospitals, and wholesalers across the entire United States are affected, necessitating widespread product retrieval and replacement efforts. Procurement directors must immediately audit their stock of Teva's Prazosin Hydrochloride, specifically checking against the numerous affected lot numbers and expiration dates provided in the recall notice. The sudden removal of nearly 300,000 bottles from the market can create localized or regional supply shortages, impacting patient access and potentially driving up spot market prices for alternative sources. Business development executives should evaluate opportunities to support the market with compliant Prazosin Hydrochloride, while regulatory affairs heads must understand the implications of such a large-scale recall on market stability and future regulatory expectations for nitrosamine testing in similar products. This event underscores the fragility of single-source or concentrated generic supply chains.
Regulatory Scrutiny on Nitrosamine Impurities and CGMP Compliance
This recall by Teva Pharmaceuticals USA, Inc. highlights the FDA's intensified focus on nitrosamine impurities in pharmaceutical products. The identification of N-nitroso Prazosin impurity C exceeding CPCA acceptable intake limits is a direct consequence of this heightened scrutiny. The Carcinogenic Potency Categorization Approach (CPCA) provides a framework for evaluating the carcinogenic risk of impurities, and exceeding these limits triggers severe regulatory action due to potential long-term health risks. Such CGMP deviations indicate failures in quality management systems, process control, or raw material testing that are fundamental to ensuring drug safety and efficacy. Regulatory affairs heads must ensure their organizations have robust nitrosamine risk assessment strategies in place, extending beyond active pharmaceutical ingredients (APIs) to excipients and manufacturing processes. This includes comprehensive testing protocols, vendor qualification, and supply chain transparency to mitigate similar risks. For business development executives, demonstrating superior quality control and compliance with evolving FDA guidelines on impurities like N-nitroso Prazosin impurity C can become a significant competitive advantage. Procurement teams need to integrate these impurity testing requirements into their supplier qualification processes, demanding evidence of rigorous nitrosamine control from all API and excipient suppliers to prevent similar disruptions and maintain product integrity. The ongoing status of this Class II recall signifies that the FDA expects thorough investigation and corrective actions from Teva.